Company

Paradigm Biopharmaceuticals Limited

Headquarters: Melbourne, VIC, Australia

CEO: Dr. Donna L. Skerrett M.D., MS

ASX: PAR +20.37%

Market Cap

A$107.0 Million

AUD as of July 1, 2024

US$71.3 Million

Market Cap History

Paradigm Biopharmaceuticals Limited market capitalization over time

Evolution of Paradigm Biopharmaceuticals Limited market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Paradigm Biopharmaceuticals Limited

Detailed Description

Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulphate sodium drugs in the injectable form for the treatment of bone marrow edema lesions, osteoarthritis, mucopolysaccharidosis, and alphaviral arthritis diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Paradigm Biopharmaceuticals Limited has the following listings and related stock indices.


Stock: ASX: PAR wb_incandescent

Details

Headquarters:

500 Collins Street

Level 15

Melbourne, VIC 3000

Australia